Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe.
Richard T CarrickCorrado De MarcoAlessio GasperettiLaurens P BosmanJean-Baptiste GourraudAlessandro TrancuccioAndrea MazzantiBrittney MurrayCatherine PendletonCrystal TichnellHarikrishna TandriKatja ZeppenfeldArthur A M WildeBrianna DaviesColette SeiferJason D RobertsJeff S HealeyCiorsti MacIntyreWael AlqarawiRafik TadrosMichael J CutlerMattia TargettiLeonardo CalòFrancesco VitaliMatteo BertiniPaolo CompagnucciMichela CasellaAntonio Dello RussoChiara CappellettoAntonio De LucaDavide StolfoFirat DuruHenrik K JensenAnneli SvenssonPia DahlbergNina E HasselbergAndrea Di MarcoPaloma JordàElena ArbeloZoraida Moreno WeidmannKarolina BorowiecAntoine DelinièreElżbieta K BiernackaJ Peter van TintelenPyotr G PlatonovIacopo OlivottoArdan Muammer SagunerKristina H HaugaaMoniek CoxClaudio TondoMarco MerloAndrew D KrahnAnneline S J M Te RieleKatherine C WuHugh CalkinsCynthia A JamesJulia Cadrin-TourignyPublished in: European heart journal (2024)
North American ARVC patients were substantially more likely than Europeans to receive primary prevention ICDs across all arrhythmic risk strata. A lower rate of ICD implantation in Europe was not associated with a higher rate of VA events in those without ICDs.